Tags

Type your tag names separated by a space and hit enter

Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases.
Int Arch Allergy Immunol. 2013; 160(1):18-26.IA

Abstract

Thymic stromal lymphopoietin (TSLP), an interleukin 7-like cytokine, can trigger dendritic cell (DC)-mediated T-helper type 2 (Th2) inflammatory responses. Recent evidence demonstrates that cytokines TSLP and OX40 (CD134)/OX40 ligand seem to be important players in the maintenance of Th2 memory pool in the pathogenesis of asthma. Accumulating data reveal that the pathogenic T cells involved in asthma are likely to be inflammatory Th2 cells. TSLP is involved in the development of asthma through crosstalk with nuclear factor NF-ĸB. Progression of skin fibrosis in atopic dermatitis occurs via TSLP/TSLP receptor. TSLP-mediated dermal inflammation aggravates experimental allergic asthma. Also, TSLP polymorphisms are associated with susceptibility to asthma, atopic dermatitis, and eczema herpeticum. These findings suggest a master switch of TSLP in the initiation of allergic and adaptive inflammation through innate pathways at the epithelial cell-DC interface. The TSLP pathway is therefore a promising target for immunotherapy of allergic diseases.

Authors+Show Affiliations

Department of Respiratory Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22948028

Citation

Wang, W L., et al. "Thymic Stromal Lymphopoietin: a Promising Therapeutic Target for Allergic Diseases." International Archives of Allergy and Immunology, vol. 160, no. 1, 2013, pp. 18-26.
Wang WL, Li HY, Zhang MS, et al. Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. Int Arch Allergy Immunol. 2013;160(1):18-26.
Wang, W. L., Li, H. Y., Zhang, M. S., Gao, P. S., He, S. H., Zheng, T., Zhu, Z., & Zhou, L. F. (2013). Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. International Archives of Allergy and Immunology, 160(1), 18-26. https://doi.org/10.1159/000341665
Wang WL, et al. Thymic Stromal Lymphopoietin: a Promising Therapeutic Target for Allergic Diseases. Int Arch Allergy Immunol. 2013;160(1):18-26. PubMed PMID: 22948028.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. AU - Wang,W L, AU - Li,H Y, AU - Zhang,M S, AU - Gao,P S, AU - He,S H, AU - Zheng,T, AU - Zhu,Z, AU - Zhou,L F, Y1 - 2012/08/30/ PY - 2012/9/6/entrez PY - 2012/9/6/pubmed PY - 2013/2/21/medline SP - 18 EP - 26 JF - International archives of allergy and immunology JO - Int Arch Allergy Immunol VL - 160 IS - 1 N2 - Thymic stromal lymphopoietin (TSLP), an interleukin 7-like cytokine, can trigger dendritic cell (DC)-mediated T-helper type 2 (Th2) inflammatory responses. Recent evidence demonstrates that cytokines TSLP and OX40 (CD134)/OX40 ligand seem to be important players in the maintenance of Th2 memory pool in the pathogenesis of asthma. Accumulating data reveal that the pathogenic T cells involved in asthma are likely to be inflammatory Th2 cells. TSLP is involved in the development of asthma through crosstalk with nuclear factor NF-ĸB. Progression of skin fibrosis in atopic dermatitis occurs via TSLP/TSLP receptor. TSLP-mediated dermal inflammation aggravates experimental allergic asthma. Also, TSLP polymorphisms are associated with susceptibility to asthma, atopic dermatitis, and eczema herpeticum. These findings suggest a master switch of TSLP in the initiation of allergic and adaptive inflammation through innate pathways at the epithelial cell-DC interface. The TSLP pathway is therefore a promising target for immunotherapy of allergic diseases. SN - 1423-0097 UR - https://www.unboundmedicine.com/medline/citation/22948028/Thymic_stromal_lymphopoietin:_a_promising_therapeutic_target_for_allergic_diseases_ L2 - https://www.karger.com?DOI=10.1159/000341665 DB - PRIME DP - Unbound Medicine ER -